Prevalence of non-convulsive status epilepticus in adults presenting with altered mental status: a systematic review and meta-analysis.

SeizureJul 30, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Amira Shaban, Hany A Zaki, Benny Ponappan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence of non-convulsive status epilepticus (NCSE) in adults with altered mental status (AMS). Analyzing data from 20 studies involving 23,068 patients, the overall prevalence of NCSE ranged from 0.1% to 49.1%. The findings highlight the significant occurrence of NCSE in this population, particularly in neurological intensive care units.

Key findings

  • Overall prevalence of NCSE in AMS patients ranged from 0.1% to 49.1%.
  • Prevalence of NCSE in NICU patients was between 10.48% and 27.5%.
  • In comatose patients, NCSE prevalence was reported at 8.1% to 8.8%.
  • NCSE accounted for 46.9% of status epilepticus cases.

Why it matters

Recognizing the prevalence of non-convulsive status epilepticus in patients with altered mental status is crucial for timely diagnosis and management, as it can significantly impact patient outcomes and treatment strategies.

What to keep in mind

Most studies included were small-scale cohort studies, limiting the power to accurately determine NCSE prevalence.

Source

PubMed · PMID 42585882

Published in Seizure. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.